OBJECTIVE: Sex steroid hormones influence bone mineral density (BMD) in women, but are less well-studied in men. We evaluated the association of serum total and free sex steroid hormones and SHBG with osteopaenia in a nationally representative sample of men aged 20-90 years. DESIGN: BMD and sex steroid hormones were measured among participants in NHANES III, a cross-sectional study of the US population. POPULATION: A total of 1185 adult men in morning examination session of Phase I of NHANES III (1988-91). MEASUREMENTS: Relation of oestradiol (E(2)), testosterone, and SHBG concentrations with BMD. Osteopaenia was defined as 1-2.5 SD below the mean for white men aged 20-29 years. RESULTS: Men in the lowest quartile of free E(2) had 70% increased odds (OR = 1.69, 95% CI 0.95-2.98) of osteopaenia compared with men in the highest quartile. Men in the lowest quartile of free testosterone had nearly four times the odds of osteopaenia than those in the highest quartile (OR = 3.82, 95% CI 1.87-7.78). Lower concentrations of SHBG appeared protective against osteopaenia (P-trend = 0.01). Neither total testosterone nor total E(2) was associated with BMD, although men with clinically low E(2) (< 20 ng/l) had lower BMD (0.930 g/cm(2), 95% CI 0.88-0.98) than men with normal-range E(2) (1.024 g/cm(2), 95% CI 1.01-1.04; P = 0.004). Findings for free E(2) were most pronounced among elderly men, while the findings for free testosterone were most pronounced among younger men. CONCLUSIONS: In this nationally representative study, men with lower free E(2), lower free testosterone, and higher SHBG concentrations in circulation were more likely to have low BMD.
OBJECTIVE: Sex steroid hormones influence bone mineral density (BMD) in women, but are less well-studied in men. We evaluated the association of serum total and free sex steroid hormones and SHBG with osteopaenia in a nationally representative sample of men aged 20-90 years. DESIGN:BMD and sex steroid hormones were measured among participants in NHANES III, a cross-sectional study of the US population. POPULATION: A total of 1185 adult men in morning examination session of Phase I of NHANES III (1988-91). MEASUREMENTS: Relation of oestradiol (E(2)), testosterone, and SHBG concentrations with BMD. Osteopaenia was defined as 1-2.5 SD below the mean for white men aged 20-29 years. RESULTS:Men in the lowest quartile of free E(2) had 70% increased odds (OR = 1.69, 95% CI 0.95-2.98) of osteopaenia compared with men in the highest quartile. Men in the lowest quartile of free testosterone had nearly four times the odds of osteopaenia than those in the highest quartile (OR = 3.82, 95% CI 1.87-7.78). Lower concentrations of SHBG appeared protective against osteopaenia (P-trend = 0.01). Neither total testosterone nor total E(2) was associated with BMD, although men with clinically low E(2) (< 20 ng/l) had lower BMD (0.930 g/cm(2), 95% CI 0.88-0.98) than men with normal-range E(2) (1.024 g/cm(2), 95% CI 1.01-1.04; P = 0.004). Findings for free E(2) were most pronounced among elderly men, while the findings for free testosterone were most pronounced among younger men. CONCLUSIONS: In this nationally representative study, men with lower free E(2), lower free testosterone, and higher SHBG concentrations in circulation were more likely to have low BMD.
Authors: P J Snyder; H Peachey; P Hannoush; J A Berlin; L Loh; J H Holmes; A Dlewati; J Staley; J Santanna; S C Kapoor; M F Attie; J G Haddad; B L Strom Journal: J Clin Endocrinol Metab Date: 1999-06 Impact factor: 5.958
Authors: E Legrand; D Chappard; C Pascaretti; M Duquenne; S Krebs; V Rohmer; M F Basle; M Audran Journal: J Bone Miner Res Date: 2000-01 Impact factor: 6.741
Authors: E Legrand; C Hedde; Y Gallois; I Degasne; F Boux de Casson; E Mathieu; M F Baslé; D Chappard; M Audran Journal: Bone Date: 2001-07 Impact factor: 4.398
Authors: Dan Mellström; Olof Johnell; Osten Ljunggren; Anna-Lena Eriksson; Mattias Lorentzon; Hans Mallmin; Anna Holmberg; Inga Redlund-Johnell; Eric Orwoll; Claes Ohlsson Journal: J Bone Miner Res Date: 2006-04-05 Impact factor: 6.741
Authors: Howard A Fink; Susan K Ewing; Kristine E Ensrud; Elizabeth Barrett-Connor; Brent C Taylor; Jane A Cauley; Eric S Orwoll Journal: J Clin Endocrinol Metab Date: 2006-07-18 Impact factor: 5.958
Authors: Britton Trabert; Barry I Graubard; Sarah J Nyante; Nader Rifai; Gary Bradwin; Elizabeth A Platz; Geraldine M McQuillan; Katherine A McGlynn Journal: Cancer Causes Control Date: 2012-09-28 Impact factor: 2.506
Authors: Jane A Cauley; Susan K Ewing; Brent C Taylor; Howard A Fink; Kristine E Ensrud; Douglas C Bauer; Elizabeth Barrett-Connor; Lynn Marshall; Eric S Orwoll Journal: J Clin Endocrinol Metab Date: 2010-06-16 Impact factor: 5.958
Authors: Meredith S Shiels; Sabine Rohrmann; Andy Menke; Elizabeth Selvin; Carlos J Crespo; Nader Rifai; Adrian Dobs; Manning Feinleib; Eliseo Guallar; Elizabeth A Platz Journal: Cancer Causes Control Date: 2009-03-10 Impact factor: 2.506
Authors: Dirk Vanderschueren; Michaël R Laurent; Frank Claessens; Evelien Gielen; Marie K Lagerquist; Liesbeth Vandenput; Anna E Börjesson; Claes Ohlsson Journal: Endocr Rev Date: 2014-09-09 Impact factor: 19.871
Authors: M Varsavsky; R Reyes-García; A García-Martín; A R González-Ramírez; R González Ramírez; M D Avilés-Perez; M Muñoz-Torres Journal: Osteoporos Int Date: 2012-05-16 Impact factor: 4.507